European Surgical Research · 2011 · 45 citations · 26 references
Our results indicate that IBSA does not modify the risk of HCC recurrence. Therefore, in highly selected HCC patients undergoing LT, the use of IBSA appears to be justified.
26
Vincenzo Mazzaferro, Josep M. Llovet, Rosalba Miceli et al. · The Lancet Oncology · 2008 · 2K citations · Full text
Gerd Otto, Sascha Herber, Michael Heise et al. · Liver Transplantation · 2006 · 410 citations · Full text
Waiting Time, Solid Organ Transplantation, Tumor Recurrence +20